COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00692172
Recruitment Status : Completed
First Posted : June 6, 2008
Last Update Posted : September 18, 2014
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
An extension study to evaluate safety and tolerability of up to 3 additional courses of IM alefacept in patients with chronic plaque psoriasis who have been previously treated with 1 or 2 courses of IM alefacept.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Alefacept Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 175 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multi-center Study to Evaluate the Safety and Tolerability of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Subjects With Chronic Plaque Psoriasis Who Have Completed Studies C99-717 or C99-712
Study Start Date : December 2001
Actual Primary Completion Date : November 2004
Actual Study Completion Date : November 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: 1 Drug: Alefacept
intramuscular injection (IM)
Other Names:
  • Amevive
  • ASP0485

Primary Outcome Measures :
  1. Assessment of safety including evaluation of incidence of adverse events, physical exams and laboratory monitoring [ Time Frame: Throughout treatment course ]

Secondary Outcome Measures :
  1. Proportion of subjects who achieved "Almost Clear" or "Clear" by Physicians' Global Assessment [ Time Frame: Every 2 weeks throughout treamtent course ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have received at least 8 injections in the C99-717 study and completed the final follow-up visit OR,
  • Must have completed the C99-712 study and been in C99-717 interim visits at the time dosing in the C99-717 study was closed. A subject who completed C99-712 but did not participate in any part of C99-717, including interim visits, must have prior sponsor approval before admission into C-728

Exclusion Criteria:

  • Nursing mothers, pregnant women, and women planning to become pregnant while on study are to be excluded. Female patients who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception during the study
  • Clinically significant abnormal hematology values or history of an immunosuppressive disorder
  • Serious local infection or systemic infection within 3 months prior to the first dose of alefacept
  • A significant change in the subject's medical history from their previous alefacept study
  • Any subject who initiated alternative systemic therapy, phototherapy, or disallowed therapy prior to visit 8 in study C99-712 or C99-717
  • Current enrollment in any investigational study in which the subject is receiving any type of drug, biologic, or non-drug therapy (participation in registry-type studies is allowed)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00692172

Layout table for location information
United States, Arkansas
Hot Springs, Arkansas, United States, 71913
United States, California
Fresno, California, United States, 93710
La Jolla, California, United States, 92037
United States, District of Columbia
Washington, District of Columbia, United States, 20010
United States, Florida
Jacksonville, Florida, United States, 32204
Pinellas Park, Florida, United States, 33781
United States, Georgia
Newnan, Georgia, United States, 30263
United States, Illinois
Chicago, Illinois, United States, 60611
United States, Kansas
Kansas City, Kansas, United States, 66160
United States, Michigan
Clinton Township, Michigan, United States, 48038
United States, Missouri
St. Louis, Missouri, United States, 63110
United States, Nebraska
Omaha, Nebraska, United States, 68131
United States, New Jersey
Berlin, New Jersey, United States, 08009
United States, Oregon
Lake Oswego, Oregon, United States, 79035
Portland, Oregon, United States, 97210
United States, Rhode Island
Johnston, Rhode Island, United States, 02919
United States, Tennessee
Goodlettsville, Tennessee, United States, 37072
United States, Texas
Austin, Texas, United States, 78759
San Antonio, Texas, United States, 78229
Brussels, Belgium, B-1070
Edegem, Belgium, B-2650
Liege, Belgium, 4000
Canada, Alberta
Calgary, Alberta, Canada, T2S 3B3
Canada, Manitoba
Winnipeg, Manitoba, Canada, R3C ON2
Canada, New Brunswick
Moncton, New Brunswick, Canada, E1C 8X3
Canada, Newfoundland and Labrador
St. John's, Newfoundland and Labrador, Canada, A1B 4S8
Canada, Ontario
London, Ontario, Canada, N6A 3H7
Waterloo, Ontario, Canada, N2J 1C
Windsor, Ontario, Canada, N8W 5L7
Canada, Quebec
Sainte-Foy, Quebec, Canada, G1V 4X7
Copenhagen, Denmark, DK-2400
Besancon, France, 25030
Brest, France, 29279
Nice, France, 06202
Paris, France, 75475
Tours, France, 37044
Bochum, Germany, 44791
Dresden, Germany, 01307
Munich, Germany, 80337
Amsterdam, Netherlands, 1100 DE
Madrid, Spain, 28006
Valencia, Spain, 46014
United Kingdom
Liverpool, United Kingdom, L14 3LB
Sponsors and Collaborators
Astellas Pharma Inc
Layout table for investigator information
Study Director: Central Contact Astellas Pharma US, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: Astellas Pharma Inc Identifier: NCT00692172    
Other Study ID Numbers: C-728
First Posted: June 6, 2008    Key Record Dates
Last Update Posted: September 18, 2014
Last Verified: September 2014
Keywords provided by Astellas Pharma Inc:
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases
Dermatologic Agents
Immunologic Factors
Physiological Effects of Drugs